

VERTEX PHARMACEUTICALS INC / MA

Form 4

November 28, 2007

**FORM 4**

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
*See* Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
BOGER JOSHUA S

(Last) (First) (Middle)

C/O VERTEX  
PHARMACEUTICALS  
INCORPORATED, 130 WAVERLY  
STREET

(Street)

CAMBRIDGE, MA 02139

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol  
VERTEX PHARMACEUTICALS  
INC / MA [VRTX]

3. Date of Earliest Transaction  
(Month/Day/Year)  
11/27/2007

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify  
below)  
President & CEO

6. Individual or Joint/Group Filing(Check  
Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V Amount (A) or (D) Price			
Common Stock	11/27/2007		M	17,500 A \$ 13.67	1,113,342	D	
Common Stock	11/27/2007		S <sup>(1)(2)</sup>	200 D \$ 24.52	1,113,142	D	
Common Stock	11/27/2007		S <sup>(1)(3)</sup>	3,800 D \$ 24.44	1,109,342	D	
Common Stock	11/27/2007		S <sup>(1)(4)</sup>	3,800 D \$ 24.34	1,105,542	D	

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Common Stock	11/27/2007	<u>S(1)(5)</u>	2,000	D	\$ 24.23	1,103,542	D	
Common Stock	11/27/2007	<u>S(1)(6)</u>	1,500	D	\$ 24.16	1,102,042	D	
Common Stock	11/27/2007	<u>S(1)(7)</u>	2,900	D	\$ 24.05	1,099,142	D	
Common Stock	11/27/2007	<u>S(1)(8)</u>	1,100	D	\$ 23.95	1,098,042	D	
Common Stock	11/27/2007	<u>S(1)(9)</u>	1,000	D	\$ 23.84	1,097,042	D	
Common Stock	11/27/2007	<u>S(1)(10)</u>	700	D	\$ 23.75	1,096,342	D	
Common Stock	11/27/2007	<u>S(1)(11)</u>	500	D	\$ 23.65	1,095,842	D	
Common Stock						12,445	I	401(k)
Common Stock						207,500	I	Shares in trust <u>(13)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option	\$ 13.67	11/27/2007		M	17,500	<u>(12)</u> 12/11/2007	Common Stock	17,500

## Reporting Owners

Reporting Owner Name / Address

Relationships

Reporting Owners

